Prenatal Testosterone Exposure Disrupts Insulin Secretion And Promotes Insulin Resistance

Albert Carrasco1*, Mónica P. Recabarren1, Pedro P. Rojas-García1, Mario Gutiérrez1, Karina Morales1, Teresa Sir-Petermann2 & Sergio E. Recabarren1

Hyperandrogenemia and metabolic disturbances during postnatal life are strongly linked both to polycystic ovary syndrome and other conditions that arise from prenatal exposure to androgen excess. In an animal model of this condition, we reported that insulin sensitivity (IS) was lower in young female sheep born to testosterone-treated mothers versus sheep born to non-exposed mothers (control). This lower insulin sensitivity remains throughout reproductive life. However, it is unknown whether abnormal postnatal levels of testosterone (T) further decrease IS derived from prenatal exposure to testosterone. Therefore, we assessed the effects of an acute testosterone administration (40 mg) on IS and insulin secretion during an intravenous glucose tolerance test performed at 40 weeks of age (adulthood) in previously ovariectomized sheep at 26 weeks of age (prepuberty), that were either prenatally exposed to testosterone (T-females, n = 6) or not (C-females, n = 6). The incremental area under the curve of insulin was greater in C-females both with or without the acute testosterone treatment (P < 0.05). The ISI-Composite was lower after an acute testosterone treatment, only in T-females. We conclude that prenatal exposure to testosterone disrupts pancreatic insulin secretion in response to glucose and that in this setting further hyperandrogenemia may predispose to lower insulin sensitivity.

Increased plasma testosterone concentrations during pregnancy could provide an anomalous intrauterine environment for a female fetus, resulting in polycystic ovary syndrome (PCOS) during reproductive life. PCOS carries hyperandrogenemia in the majority of cases but also metabolic disarrangements such as relative hyperinsulinemia and insulin resistance, two features that predispose to cardiovascular diseases and. Reduced insulin sensitivity promotes the release of more insulin by the pancreas in order to compensate and achieve its biological effects.

The relationship between androgens and insulin in PCOS patients deserves more understanding to comprehend the pathophysiology of the syndrome. Insulin can increase circulating androgens by a complex molecular mechanism involving the insulin receptor substrate 1 (IRS-1) in the ovaries and the adrenal gland. Metformin, an insulin sensitizer, can reduce hyperinsulinemia to normal levels, but it also reduces hyperandrogenemia. However, less is known about the effects of testosterone on insulin secretion and whether it is involved in the pathogenesis of the metabolic condition in PCOS. Adult women diagnosed with PCOS have a higher incidence of insulin resistance when their free testosterone concentrations are higher, suggesting a deleterious effect of plasma testosterone concentrations on insulin resistance.

Divergent effects of testosterone on pancreatic tissue have been reported in vivo and in vitro, making it difficult to predict a precise role for testosterone on insulin secretion. A stimulatory effect of testosterone on insulin secretion has been reported in men, in whom lower testosterone levels are associated with insulin resistance. In vitro exposure of pancreatic tissue to testosterone increase insulin synthesis and secretion, whereas gonadectomy decreases both processes in male rats, suggesting a direct effect of androgens on pancreatic beta cell function. In βARKO male mice, which lack the expression of the androgen receptor (AR) in pancreatic beta cells, a decrease in glucose-stimulated insulin secretion has been observed. Furthermore, dihydrotestosterone (DHT) acts as an insulinotropic agent. In addition, it has been postulated that testosterone has a protective role on pancreatic beta cells, perhaps mediated by the androgen receptor. Therefore, testosterone could have supportive or beneficial...
roles for the secretion of insulin by the pancreas. The offspring of monkey and sheep prenatally exposed to testosterone excess, show programming effects, that culminate in insulin resistance during postnatal life\(^1\)\(^2\). In PCOS animal models the role of testosterone on insulin resistance is not clear.

In order to explore the effect of prenatal androgen exposure and of adult hyperandrogenemia on insulin we studied insulin secretion and sensitivity before and after a single dose of testosterone in ovariectomized ewes, exposed and not exposed prenatally to testosterone.

Materials and Methods
General management and group allocation. All procedures, management and experimental methodologies were previously revised and approved for the Ethical Committee in Animal Research of the Faculty of Veterinary Science of the Universidad de Concepción, Chile and were performed in agreement with the International Guiding Principles for Biomedical Research Involving Animals and Bioethics Advisory Committee of the Chilean National Commission for Scientific and Technological Research (CONICYT, Chile).

Adult female Suffolk-Down sheep were randomly selected for estrous synchronization and mated with rams of proven fertility. The day of mating was recorded and after pregnancy was confirmed by ultrasonography, dams were allocated randomly to be or not to be treated. Treated dams received biweekly intramuscular injections of 30 mg of testosterone (Testosterone propionate, Steraloids, USA) dissolved in 1 ml of vegetable oil per animal, from days 30 to 90 of gestation and thereafter biweekly injections with 40 mg of testosterone per animal until day 120 of gestation. Control dams were injected with vehicle of testosterone following the same schedule. Dams had access to pasture and hay, supplemented with pelleted food according to feeding protocols for pregnant sheep. On day 120 of pregnancy blood samples were collected from pregnant dams by venipuncture after an overnight fast and plasma testosterone concentrations were determined afterwards.

Immediately after birth (~147 days), all newborn lambs were weighed and then left undisturbed to facilitate mother-lamb interactions and to ensure colostrum intake. Lambs were kept with their mothers under natural photoperiod and with free access to water and were weaned at 8-weeks of age. Lamb grouping were assigned as T-females for those born to testosterone-treated dams and C-females for those born to control dams. All females were subjected to a bilateral ovariectomy under general anesthesia at 24 weeks of age in order to mitigate the influence of naturally produced androgens derived from the ovary\(^6\). Sheep did not receive exogenous estradiol or progesterone after ovariectomy.

Experimental protocol for intravenous glucose tolerance test (IVGTT) and testosterone acute treatment. The experimental protocol was designed to evaluate insulin secretion and insulin sensitivity by means of an IVGTT in adult (40–42 weeks of age) ovariectomized T-females and C-females sheep (~14–16 weeks after ovariectomy). The first IVGTT was performed at 40 weeks of age. There test was performed without the influence of exogenous androgens administration; in order to determine effects of prenatal exposure to testosterone on insulin sensitivity without the influence of testosterone. The second IVGTT was performed at 42 weeks of age, and it was performed 48 hours after an intramuscular injection of 40 mg of testosterone propionate (Steraloids, USA) dissolved in 1 ml vegetable oil. Both C-females and T-females received the treatment. This second test allowed us to determine the effects of plasma testosterone in addition to a prenatal exposure to testosterone on insulin sensitivity and the effect of testosterone per se on insulin sensitivity by comparing each group separately.

For the IVGTT, bilateral jugular vein catheterization was done. For acclimation, three blood samples were collected prior to the study. Sheep were placed in experimented crates the night before the study and fasted overnight (12 hours). The IVGTT consisted of an infusion, over a 2-minutes interval, of a glucose solution (300 mg glucose/kg body weight\(^0\)\(^{0.75}\), as described\(^15\). At 20 minutes after the start of the glucose infusion, an intravenous bolus of human insulin (0.1 IU/kg body weight, Humulin-R EllyLilly, Santiago, Chile) was administered. Blood samples (1.5 ml) were collected at -15–10, 0 (glucose infusion) and 3, 5, 7, 10, 13, 15, 17, 20 (insulin infusion), 23, 25, 27, 30, 33, 35, 37, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170 and 180 minutes after the start of the glucose infusion. Blood samples were placed in two series of tubes. One series contained sodium chloride 3% and heparin (for glucose) and the others, contained heparin (1IU/ml blood), for insulin determination. Blood samples were centrifuged at 1,000 x g for 10 minutes at 4°C. Plasma was collected and deposited in microtubes and stored at -20°C pending quantification of plasma concentrations of glucose and insulin. Plasma testosterone concentration was measured in the time 0 sample.

Glucose, insulin and testosterone determination. Plasma glucose concentrations were quantified by a commercial kit (Farmalatina, Chile), based on the glucose oxidase and peroxidase reaction, with measurement of the light absorbance at 505 nm wavelength in a spectrophotometer. Plasma insulin concentrations were determined by IRMA (Biosource, Belgium). Minimal detectable insulin concentration was 1 μU/ml. Intra- and inter-assays coefficients of variation were 2.68% and 2.63%, respectively. Plasma testosterone concentrations were determined by radioimmunoassay with commercial kit (Biosource, Belgium) in one single assay. The minimal detectable level of testosterone was 0.01 ng/ml and the intra-assay coefficient of variation was 3.92%.

Indices of insulin sensitivity and insulin production in response to glucose infusion. We determined the following three end points: i) Fasting insulin-to-glucose ratio (I/G ratio), using mean concentrations of insulin and glucose in plasma samples obtained at -15, -10, and 0 min of glucose infusion (basal samples); ii) Composite insulin sensitivity index (ISI-C), based on formula developed by Matsuda and De Fronzo\(^16\), where ISI-C = 10000/square root of ((fasting glucose × fasting insulin) × (mean glucose × mean insulin during the first 20 min of IVGTT)); and iii) Glucose disappearance rate (GDR), where glucose response to the exogenous insulin injection was calculated using the formula described by Gruet et al\(^17\). Production of insulin by pancreatic β...
Comparison test (Fig. 2, panel A). Insulin levels increased significantly at 3 minutes post glucose infusion and glucose levels between groups was detected at 3 minutes after glucose administration by means of a multiple comparison test (Table 1).

Plasma testosterone were compared between groups with an unpaired Student's t-test. Statistical analyses were performed with GraphPad Prism® version 6.0 software, in which P values of 0.05 were considered different. Data are shown as mean ± standard error.

**Results**

**Body weight in ovariectomized sheep.** Mean body weight was similar between C-females and T-females except at birth, when T-females were significantly heavier than C-females (Table 1).

**Testosterone levels in pregnant sheep and ovariectomized sheep.** Treatment with testosterone propionate in the T-mothers was effective in rising plasma levels of testosterone, while control mothers treated with vehicle, showed undetectable levels (Table 2). In ovariectomized sheep, testosterone levels were undetectable by the time of the first IVGTT at 40 weeks of age, while the acute exposure to testosterone was able to increase testosterone levels in both groups of sheep 48 hours after the injection by the time of the second IVGTT (Table 2).

**Effects of prenatal exposure to T on insulin secretion and insulin sensitivity in absence of an acute exposure to testosterone. Comparisons between C-females and T-females.** The insulin-to-glucose ratio, determined in basal samples, as well as the ISI-C and the glucose disappearance rate determined after the first IVGTT, were not significantly different between C- and T-females (Fig. 1A–C, left side of the graph). However, the incremental AUC of insulin (AUC-I) was significantly lower in T-females (Fig. 1D, left side of the graph).

Glucose concentrations increased significantly 3 minutes after glucose infusion (Fig. 2) and remained high during the first 20 minutes of the IVGTT in both groups (P < 0.05, Time factor F(8,90) = 15.03). A difference in glucose levels between groups was detected at 3 minutes after glucose administration by means of a multiple comparison test (Fig. 2, panel A). Insulin levels increased significantly at 3 minutes post glucose infusion and remained high for the first 20 minutes in C-females, whereas in T-females the increase started at 5 minutes and remained high until minute 13, indicating an effect of time (P < 0.0001, F(8,90) = 10.24) and of prenatal treatment (P < 0.0001, F(1,90) = 32.07). A delay in the peak of insulin was observed in both groups. At 10 min after of the glucose infusion, T-females showed lower insulin concentrations (Fig. 2, panel C).

| Age                      | C-females (n = 6) | T-females (n = 6) |
|--------------------------|------------------|------------------|
| Birth                    | 3.5 ± 0.16       | 4.5 ± 0.17*      |
| 24 weeks (ovariectomy)   | 25.5 ± 1.80      | 24.6 ± 1.20      |
| 40 weeks (IVGTT pre acute T) | 34.1 ± 2.00     | 30.8 ± 1.20      |
| 42 weeks (IVGTT post acute T) | 32.7 ± 1.80     | 29.8 ± 1.20      |

**Summary of testosterone plasma concentrations (ng/ml) in pregnant sheep and ovariectomized sheep during testosterone treatments.** *Difference (P < 0.05) between groups within a sample time. a,b Difference (P < 0.05) between groups in presence or absence of acute testosterone treatment. *Mothers corresponded to pregnant sheep (T-treated) with intramuscular injections of testosterone propionate 30 mg twice per week from day 30 to 90 and 40 mg twice per week from day 91 to 120 of pregnancy. Control dams received the vehicle of the hormone during the same time intervals. *Correspond to control females (C-females) and prenatally exposed to T females (T-females) treated with an acute testosterone injection 48 hours prior to an intravenous glucose tolerance test. *Difference between groups (P < 0.05).

Table 1. Body weights (Kg) of control (C-females) and prenatally T exposed (T-females) ovariectomized sheep at various ages. *Difference between groups (P < 0.05). *Acute testosterone (T) treatment with 40 mg intramuscular/animal. Levels of T measured by the time of each intravenous glucose tolerance test (IVGTT).
Effect of an acute exposure to testosterone on insulin secretion and insulin sensitivity without prenatal exposure to testosterone. Analysis in C-female sheep.

None of the indices of insulin sensitivity or of insulin secretion were significantly changed by the acute treatment with testosterone in C-females (Fig. 1, open bars). In the serial display of glucose and insulin levels it is possible to observe that the levels are similar between the pre and post testosterone situations, except for minute 17 post glucose infusion, where the levels of insulin were higher under testosterone treatment (Fig. 2, panel C and D, open circles).

Effect of an acute exposure to testosterone on insulin secretion and insulin sensitivity without prenatal exposure to testosterone. Analysis in C-female sheep. None of the indices of insulin sensitivity or of insulin secretion were significantly changed by the acute treatment with testosterone in C-females (Fig. 1, open bars). In the serial display of glucose and insulin levels it is possible to observe that the levels are similar between the pre and post testosterone situations, except for minute 17 post glucose infusion, where the levels of insulin were higher under testosterone treatment (Fig. 2, panel C and D, open circles).

Effect of an acute exposure to testosterone on insulin secretion and insulin sensitivity in prenatally exposure to testosterone. Analysis in T-female sheep. Acute exposure to testosterone caused a significant decrease in ISI-C in T-females (Fig. 1, panel B, closed bars). The AUC-I of insulin, which was already lower due to the prenatal exposure to testosterone, did not change with the acute administration of testosterone in T-females, indicating
that insulin secretion by the pancreas was not damaged by an acute testosterone treatment. The other parameters of insulin sensitivity were unaltered (Fig. 1, closed bars).

**Effect of prenatal exposure to testosterone on insulin secretion and insulin sensitivity after testosterone administration. Comparisons between C- and T-females.**

Similar to the analysis between both groups in absence of an acute exposure to testosterone, T-females showed a significantly lower AUC-I, which indicates that, despite hyperandrogenemia, T-females continue showing a lower secretion of insulin, therefore, the prenatal exposure to testosterone has a major impact on reducing insulin secretion (Fig. 1C, right side of the graph).

The serial display of plasma levels of glucose and insulin along the first 20 minutes of the IVGGT shows that glucose levels rose significantly in both groups, exhibiting a similar pattern not affected by the acute testosterone treatment. According to the ANOVA test insulin levels showed a significant effect of time ($P < 0.001$, $F(8,90) = 6.34$) and of the prenatal exposure to testosterone ($P < 0.001$, $F(1,90) = 31.45$). As observed in the IVGGT without acute T, both groups showed a delayed peak of insulin. At min 17 after glucose, C-females showed a significantly higher level of insulin (Fig. 2).

**Discussion**

We determined whether induced hyperandrogenemia in the absence of the ovaries, has an impact on insulin resistance in ewes prenatally exposed to testosterone. We concluded that hyperandrogenemia lowered insulin sensitivity if there was a previous prenatal exposure to testosterone excess, but also that prenatal exposure to testosterone, regardless of the presence of hyperandrogenemia, decreased glucose-induced secretion of insulin which is consistent with pancreatic reprogramming.

**Developmental programming of testosterone on insulin secretion.** The endocrine pancreas is susceptible to programming. In particular, secretory functions of the beta pancreatic cell can be targeted during fetal development at various levels. Among PCOS-like models, this is apparently one of the few studies elucidating the role of fetal exposure to testosterone on pancreatic development and metabolic functions. The fact that T-females had a lower incremental AUC of insulin compared to C-females either with or without the acute testosterone treatment, suggest the presence of testosterone programming, manifested as a lower response to a glucose load. Whether this programming involved a reduced sensitivity of the pancreas to glucose or an impaired insulin synthesis, cannot be established in our model. Other animal models of PCOS, using three times the testosterone dose we used in our model, have shown increased numbers of pancreatic beta cells during adulthood, with no significant effects on beta cell number in the fetus. However, testosterone treatment (20 mg), administered directly to the fetus, increased the number of pancreatic beta cells. This direct testosterone infusion into the fetus also increase insulin secretion after a glucose load at 11 months of age, indicating a fetal programmed hyperinsulinemia, which is likely to be an end result of insulin resistance. We did not see comparable results in our model. Our results, in fact, show metabolic outcomes that seems...
in opposition to those previously reported, even considering that the glucose challenges were performed at comparable ages (40–42 weeks vs. 11 months). The source of this difference could lie in a lower dose of testosterone given to our animals that could impact in a differential way. The dose of testosterone we use is intended to resemble both the pattern of increase in plasma testosterone and the plasma concentration of testosterone observed in pregnant PCOS women, which recreates a more realistic environment on the fetus. In this setting our results are similar to what has been described in human PCOS. Preliminary experiments from our laboratory have shown a decrease in the total area of the Langerhans islets at 120 days of sheep fetal life under this regimen, which could partially explain the decrease in insulin secretion after a glucose load. The fact that T-females weighed less at birth can point out to a possible reduction in the size of the pancreas as well. Liu et al. suggest an increase in systemic oxidative stress after acute exposure to testosterone coupled to a previous injury in beta cells by prenatal exposure to testosterone, mediated by mechanisms involving the androgen receptor. Interestingly, young male rhesus monkeys prenatally exposed to testosterone also exhibit impaired insulin secretion, without necessarily having high levels of circulating androgens, which suggests a programming effect upon the pancreas. Therefore, our results suggest a programmed failure of the pancreatic beta cells due to a prolonged exposure to testosterone during fetal development.

**Effect of androgenemia on insulin resistance.** Hyperandrogenemia is a common feature in PCOS and can increase the risk of insulin resistance. In the present study, a brief hyperandrogenemia reduced the ISI-C only in ewes that were prenatally exposed to testosterone, suggesting that hyperandrogenemia may decrease peripheral sensitivity to insulin. There are reports of testosterone administration to ovariectomized female rats causing a clear insulin resistance. Although, testosterone did not significantly affect insulin sensitivity in C-females, negative effects of testosterone on insulin sensitive tissues have been previously reported. Subcutaneous adipocytes isolated from healthy women and treated in vitro with testosterone, had delayed glucose uptake, due to a decrease in the insulin induced phosphorylation of PKC, with no comprise of the upstream insulin signaling, suggesting that testosterone can directly induce insulin resistance in adipose tissue. Adipocytes isolated from PCOS women have reduced glucose uptake, suggesting a disturbance in insulin binding and phosphorylation of its receptor or a lower GLUT4 translocation. Pre-menopausal women with increased androgens have increased insulin resistance demonstrated by the HOMA model, as well as increased insulin secretion after a glucose load. Recent studies shown that testosterone has specific effects on the adipose tissue of pre-menopausal women increasing pro-inflammatory cytokines, which can affect tissue responses to insulin. Similar animal models have shown differential sensitivity to insulin with liver and skeletal muscle being insulin resistant, and an adipose tissue that remains insulin sensitive. The underlying mechanism involved in insulin resistance in women with PCOS remains somewhat elusive. Since in our model the hyperinsulinemia does not coexist with the hyperandrogenemia, as it has been observed in women with PCOS, but the peripheral IR is still present, as in women with PCOS, the impact that fetal programming has on the response to hyperandrogenemia is critical and can suggest that the origin of this syndrome lies in fetal programming and that hyperinsulinemia is more a consequence than a cause of it.

In summary, prenatal exposure to testosterone induced a programming of the capacity of the pancreas to secrete insulin in response to glucose and predisposes the insulin sensitive tissue to a lower response when challenged with higher testosterone concentrations.

**Data availability**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 25 July 2019; Accepted: 9 December 2019;
Published online: 15 January 2020

**References**

1. Abbott, D. H., Barnett, D. K., Bruns, C. M. & Dumesic, D. A. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? *Hum. Reprod. Update* 11, 357–374 (2005).
2. Pasquali, R. et al. Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. *J. Clin. Endocrinol. Metab.* 101, 2013–2022 (2016).
3. Yildiz, B. O., Bozdag, G., Yapici, Z., Esimli, I. & Yarali, H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. *Hum. Reprod. 27*, 3067–3073 (2012).
4. Mather, K. J., Kwan, F. & Corenblum, B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. *Fertil. Steril. 73*, 150–156 (2000).
5. Wilcox, G. Insulin and insulin resistance. *Clin. Biochem. Rev.* 26, 19–39 (2005).
6. Baptiste, C. G., Battista, M. C., Trottier, A. & Baillargeon, J. P. Insulin and hyperandrogenism in women with polycystic ovary syndrome. *J. Steroid Biochem. Mol. Biol.* 122, 42–52 (2010).
7. Nascimento, A. D., Silva-Lara, L. A., Japar de Sá Rosa-e-Silva, A. C., Ferriani, R. A. & Reis, R. M. Effects of metformin on serum and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. *Gynecol. Endocrinol.* 29, 246–249 (2013).
8. Liu, L. et al. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. *Clin. Med. J. (Engl.) 124*, 714–718 (2011).
9. Lerchebaum, E., Schwetz, V., Giuliani, A., Pieber, T. R. & Obermayer-Pietsch, B. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. *Fertil. Steril.* 98, 1318–1325 (2012).
10. Pitteloud, N. et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. *Diabetes Care* 28, 1636–1642 (2005).
11. Mortimo, S. et al. Protective effect of drug on early apoptotic damage induced by streptozotocin in rat pancreas. *J. Endocrinol.* 187, 217–224 (2005).
12. Navarro, G. et al. Extraneural actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. *Cell Metab.* 23, 837–851 (2016).
13. Zitzmann, M. Testosterone deficiency, insulin resistance and the metabolic syndrome. *Nat. Rev. Endocrinol.* 5, 673–681 (2009).
14. Eisner, J. R., Dumesci, D. A., Kennitz, J. W. & Abbott, D. H. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J. Clin. Endocrinol. Metab. 85, 1206–1210 (2000).
15. Recabarren, S. E. et al. Postnatal consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am. J. Physiol. Endocrinol. Metab. 289, 801–806 (2005).
16. Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).
17. Gruet, H., Durlach, V., Hecart, A. C., Gross, A. & Leutenegger, M. Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index. Diabetes Res. Clin. Pract. 20, 201–207 (1993).
18. Fowden, A. L. & Hill, D. J. Intra-uterine programming of the endocrine pancreas. Br. Med. Bull. 60, 123–142 (2001).
19. Rae, M. et al. The pancreas is altered by in utero androgen exposure: implications for clinical conditions such as polycystic ovary syndrome (PCOS). PLoS ONE 8, e56263, https://doi.org/10.1371/journal.pone.0056263 (2013).
20. Ramaswamy, S. et al. Developmental programming of polycystic ovary syndrome (PCOS): prenatals androgens establish pancreatic islet α/β cell ratio and subsequent insulin secretion. Sci Rep. 6, 27408, https://doi.org/10.1038/srep27408 (2016).
21. Sir-Petermann, T. et al. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum. Reprod. 17, 2573–2579 (2002).
22. Recabarren, M. et al. Long-term testosterone treatment during pregnancy does not alter insulin or glucose profile in a sheep model of polycystic ovary syndrome. J. Matern. Fetal Neonatal Med. 32, 173–178 (2019).
23. Maliqueo, M. et al. Proinsulin serum concentrations in women with polycystic ovary syndrome: a marker of β-cell dysfunction? Hum. Reprod. 118, 2663–2668 (2003).
24. Sandoval, D. et al. Impact of the hyperandrogenic intrauterine microenvironment on development and function of fetal beta cells in females. XXVII Annual Meeting of the Chilean Society for Reproduction and Development 2–5 September, Antofagasta, Chile (2016).
25. Fowden, A. L. & Comline, R. S. The effects of pancreatectomy on the sheep fetus in utero. J. Exp. Physiol. 69, 319–330 (1984).
26. Liu, S. et al. Androgen excess produce systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One 24, e11302, https://doi.org/10.1371/journal.pone.0011302 (2010).
27. Bruns, C. et al. Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. J. Clin. Endocrinol. Metab. 89, 6218–6223 (2004).
28. Holmäng, A., Svedberg, J., Jennische, E. & Björntorp, P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am. J. Physiol. 259, E555–E560 (1990).
29. Corbould, A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J. Endocrinol. 192, 585–594 (2007).
30. Ciardali, T. P. et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 75, 577–583 (1992).
31. Rosenbaum, D., Haber, R. S. & Dunia, F. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am. J. Physiol. 264, E197–E202 (1993).
32. Ivanići, A. et al. Insulin resistance and androgens in healthy women with different body fat distributions. Wien. Klin. Wochenschr. 114, 321–326 (2002).
33. Crisosto, N. et al. Testosterone increases CCL-2 expression in visceral adipose tissue from obese women of reproductive age. Mol. Cell. Endocrinol. 44, 59–66 (2017).
34. Lu, C. et al. Developmental programming: prenatal testosterone excess and insulin signaling disruptions in female sheep. Biol. Reprod. 94(113), 1–11, https://doi.org/10.1095/biolreprod.113.136283 (2016).
35. Kaufman, R. P., Baker, T. E., Baker, V. M., DiMarino, P. & Castracane, V. D. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am. J. Obstet. Gynecol. 198, 670, e1–e70.e7 (2008).

Acknowledgements
We thank to Dr. Manuel Maliqueo, Dr. Nicolás Crisosto and Bárbara Echiburú for his assistance in reviewing and preparing the manuscript, to Mr. José García and Dr. Felipe Díaz for the excellent care provided to the experimental animals and to the undergraduate students of the Veterinary Medicine career of the Universidad de Concepción for their collaboration and assistance during the experiments. This work was supported by FONDECYT grant #1140433.

Author contributions
Animal work was performed by A.C., M.R., P.R., M.G., K.M., A.C., M.R., P.R., T.S. and S.R. performed laboratory analyses and developed techniques. A.C., M.R., P.R., M.G., K.M., T.S. and S.R. analyzed data sets and prepared manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to A.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020